Literature DB >> 19860718

Characterisation of oxidized recombinant human galectin-1.

Stacy A Scott1, Andrea Bugarcic, Helen Blanchard.   

Abstract

Oxidized human galectin-1 plays a role in the immune response to injured axons. Over-expression of galectin-1 by cancer, in combination with cancer associated oxidative stress suggests oxidized human galectin-1 may also play a role(s) in tumourigenesis. Here we generate milligram quantities of oxidized human galectin-1 and undertake biophysical characterization. The protein adopts a number of different states. Two separable oxidized forms are identified that exist as largely mono-disperse solutions at higher milligram/ml concentrations. The presence of disulphide bonds is confirmed for these two protein forms, as is their change in overall shape and loss of lectin activity. Our studies lead to production of a particular mono-disperse oxidized human galectin-1 species that is anticipated most optimal for investigations requiring milligram/ml concentrations such as X-ray crystallography.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19860718     DOI: 10.2174/092986609789071342

Source DB:  PubMed          Journal:  Protein Pept Lett        ISSN: 0929-8665            Impact factor:   1.890


  2 in total

1.  Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress.

Authors:  Koichi Ito; Stacy A Scott; Samuel Cutler; Lan-Feng Dong; Jiri Neuzil; Helen Blanchard; Stephen J Ralph
Journal:  Angiogenesis       Date:  2011-04-27       Impact factor: 9.596

2.  Galectin-1 dimers can scaffold Raf-effectors to increase H-ras nanoclustering.

Authors:  Olga Blaževitš; Yonatan G Mideksa; Maja Šolman; Alessio Ligabue; Nicholas Ariotti; Hossein Nakhaeizadeh; Eyad K Fansa; Anastassios C Papageorgiou; Alfred Wittinghofer; Mohammad R Ahmadian; Daniel Abankwa
Journal:  Sci Rep       Date:  2016-04-18       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.